groups had higher pan (total) SNAP-25 BA9/BA24 ratios than normal controls. These data expand our understanding of clinical factors associated with SNAP-25. They suggest that SNAP-25 total and isoform levels may be useful biomarkers beyond limited neurological and psychiatric diagnostic categories.
Introduction
The 25-kDa synaptosomal-associated protein (SNAP-25) is a T-SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein) [1, 2] which acts in concert with the integral membrane protein syntaxin [3] , allowing neuronal vesicles to attach to the plasma membrane and release its content in response to calcium signaling. There are two SNAP-25 isoforms, and they are widely expressed with both regional and cellular compartment specificity [4, 5] . The isoforms arise from alternative splicing of exon 5 and are developmentally regulated [6] . SNAP-25a is the dominant form prenatally, and SNAP25b predominates after birth in humans. SNAP-25 is involved in most neurotransmissions, including acetylcholine, glutamate, GABA, dopamine and serotonin [7] [8] [9] [10] [11] .
Changes in SNAP-25 can either be a reflection of altered neurotransmission, or it can directly change neurotransmission with downstream-altered behavior. For example, an amino acid substitution of the protein kinase C phosphorylation site on SNAP-25 produces anxiety behavior with a working memory deficit [7] , and phosphorylated SNAP-25 is associated with acute stress [8] . Further supporting the idea of a critical role of SNAP-25 in human brain disorder are numerous studies which associate total, but not isoform, levels of SNAP-25 with bipolar disorder (BP), schizophrenia [12] [13] [14] [15] [16] [17] , attention deficit hyperactivity disorder, chronic pain [16, 18, 19] , anxiety and epilepsy [20] .
In this work, we wanted to determine if there were differential SNAP-25 isoform levels based on variables such as psychiatric diagnoses, medication use, alcohol use and the level of emotional symptoms at the end of life. To accomplish this, we studied two brain areas thought to be involved in the pathology of both neurological and psychiatric disorders, including BP and schizophrenia [21, 22] : the dorsolateral prefrontal cortex [Brodmann's area (BA) 9] and the anterior cingulate cortex (ACC; BA24). In these areas, we measured SNAP-25 mRNA expression and protein levels of normal controls, individuals who had BP and those who had schizophrenia.
Materials and Methods

Subjects
This study examines SNAP-25 isoform mRNA expression and protein levels from the postmortem prefrontal cortex in control (n = 12), BP (n = 9) and schizophrenia (n = 8) subjects. A trained clinician interviews the next of kin (NOK) about the donor (psychological autopsy) to provide diagnostic information and information about mood state (lifetime and in the last week of life). To establish the clinical diagnosis, a DSM-IV-based Mini-International Neuropsychiatric Interview (MINI) [23] is administered to the NOK about the deceased. Information from these interviews, in addition to a review of all available medical records, is presented to the expert diagnostician consensus group, whose inter-rater reliability for the MINI was 0.8 for BP and schizophrenia. Medications listed are those that were prescribed at the time of death. Mood state in the last week of life is determined via semi-structured interviews. The Bipolar Inventory Symptoms Scale (BISS) [24] generates a total severity score and 5 symptom factor scores including mania, depression, anxiety, irritability and psychosis [25] . Lifetime impulsivity is measured using the Barratt Impulsiveness Scale [26] .
Postmortem Tissue
The cerebrum was hemisected and cut into 1-cm-thick coronal blocks starting at the frontal pole, digitally photographed to document anatomical location, immediately frozen in isopentane (2-methylbutane, Fisher), chilled with dry ice to -60 ° C, and then stored at -80 ° C. A neuropathologist examined all brain samples for both gross and microscopic neuropathology. All subjects included in this study were free of confounding neuropathology. Toxicology results were obtained from the Bexar County Forensic Toxicology Laboratory. Psychotropic medication was identified in 13 of the 17 affected subjects ( table 1 ) . Control tissue was toxicology free of drugs of abuse. Table 1 lists the causes of death and toxicological results. For tissue identification of BA9 (dorsolateral prefrontal cortex) and BA24 (ACC), we used the criteria described by Rajkowska and Goldman-Rakic [27] .
Microfluidic High-Throughput RT-qPCR Eighty milligrams of frozen tissue was dissected from BA9 and BA24, and total RNA was isolated using the RNeasy Lipid Tissue Mini Kit (Qiagen, Valencia, Calif., USA), per instructions; 100 μg of RNA was reverse transcribed utilizing the High-Capacity RNAto-cDNA kit (Life Technologies, Grand Island, N.Y., USA). The cDNA was used as a template for microfluidic high-throughput RT-qPCR on the Fluidigm Biomark (San Francisco, Calif., USA) [28] . The cDNA was preamplified according to the Fluidigm Gene Expression Specific Target Amplification protocol using TaqMan PreAmp Master Mix and the following TaqMan gene expression assay primer/probes (Life Technologies/Applied Biosystems): pan SNAP-25 (primer spans exon 5 and encompasses both a and b isoforms) #Hs00268296_m1; SNAP-25b #Hs00938966_m1; SNAP25a #Hs00938960_m1; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) #4333764F.
The amplified product was diluted 1: 5, mixed with TaqMan Universal PCR Master Mix (2×; Life Technologies, PN 4304437) and GE Sample Loading Reagent (20×; Fluidigm, PN 85000746), and loaded onto the sample wells of the 48.48 Dynamic Array integrated fluidic circuit (IFC). The TaqMan assay primer/probes were diluted to 10× concentration and loaded onto the assay wells of the IFC. Assay samples were run in duplicate, thus generating duplicates per sample in one IFC. qPCR was performed according to the Biomark protocol as follows: 2 min at 50 ° C, 10 min at 95 ° C, followed by 40 cycles of 95 ° C for 15 s and 60 ° C for 60 s. Data were processed by user detector threshold settings (each gene has independent thresholds) and linear baseline correction using Biomark Real-Time PCR Analysis software (v.3.0.4).
Relative quantification of the gene products was calculated using the ΔC t method [29] and transformed using 2 -ΔCt , with GAPDH as the endogenous control. This gene was chosen as the reference gene due to general stability and minimal variation across diagnostic groups [30] . We found no significant differences in gene expression of GAPDH in BA9 [F(2, 16) = 0.96, p = 0.40] or in BA24 [F(2, 15) = 3.1, p = 0.08] across diagnostic groups in this cohort of subjects.
Western Blotting
In brief, 50 mg of tissue was homogenized in 5× volume of cold 0.05 M Tris-buffered saline (pH 7.4) with protease inhibitor cocktail (Sigma Chemical Company No. P8340) and 1% NP-40 at 4 ° C. The homogenate was centrifuged for 10 min at 1,000 g at 4 ° C. The pellet (P1) was resuspended in 100 μl of homogenization buffer and centrifuged for 15 min at 12,000 g at 4 ° C. The pellet (P2) was resuspended in 300 μl of homogenization buffer, and protein concentration was determined using the Bradford method. Samples were denatured with the addition of Laemmli buffer and β-mercaptoethanol and heated to 95 ° C for 5 min. All samples were standardized, and 5 μg of total protein was electrophoresed on a SNAP-25a and b isoform-specific antibodies [4] were used for immunodetection. The blots were incubated for 1 h on a shaker at 24 ° C in either rabbit anti-SNAP-25a antibody (1: 2,000) with mouse anti-β-actin antibody (Sigma, Cat. No. A1978; 1: 10,000) in Odyssey Blocking Buffer or SNAP-25b (1: 4,000) with mouse anti-β-actin antibody (Sigma, Cat. No. A1978; 1: 10,000) in Odyssey Blocking Buffer. The blots were rinsed 3 times in Tris-buffered saline with 1% Tween 20 (TTBS) for 5 min each and then incubated in the secondary antibody for 1 h in the dark, at room temperature with constant shaking. Near-infrared (IR) dye-tagged secondary antibodies from Rockland Immunochemicals Inc. (Gilbertsville, Pa., USA) were utilized as follows: anti-rabbit IgG IRDye 700DX conjugated (1: 4,000) was used to detect SNAP-25a and SNAP-25b, and anti-mouse IgG IRDye 800CW conjugated (1: 10,000) was used to detect β-actin. The blots were rinsed again 3 times for 5 min in TTBS and visualized using an Odyssey Imaging System (LI-COR Biotechnology). SNAP-25a and b isoforms were measured at 700 nm and β-actin at 800 nm.
The samples were run in duplicate and values averaged. Data are expressed as the relative SNAP-25 level = immunointensity of SNAP-25 isoform/immunointensity of β-actin.
Statistics SPSS Statistics version 20 (Chicago, Ill., USA), was used for the analysis. Normally distributed data were analyzed with the univariate analysis of covariance (ANCOVA) and post hoc correction by the Bonferroni method. When comparing groups according to psychiatric diagnoses (BP, schizophrenia, normal control) and with the alcohol use disorder (AUD) groups (AUD, no AUD, normal control), nonnormally distributed data [SNAP-25 pan (total) BA9 mRNA, SNAP-25 pan (total) BA24 mRNA , SNAP-25b/a BA9 protein ratio, symptom scales] were analyzed with the Mann-Whitney U test. Pairwise comparison was performed with the Kruskal-Wallis test. We used the Mann-Whitney U test to compare ethnicity (Hispanic, Anglo-American) and smoking (yes, no) groups. Categorical data were compared between groups by χ 2 analysis. We used the Spearman correlation to look at pH and SNAP-25 along with comparing mRNA with protein levels. One subject in the normal control group and 1 subject in the BP SNAP-25b/a BA9 protein group were outliers by >2 standard deviations from the mean, and these measurements were not included in the analysis.
Results
SNAP-25 Protein Levels
Protein levels of SNAP-25a and SNAP-25b isoforms were examined in BA9 and BA24 of the prefrontal cortexes from bipolar, schizophrenia and normal control subjects. Figure 1 shows the detection of single bands for SNAP-25 isoform a and b proteins at the predicted molecular weight. We also looked at the ratio of SNAP isoforms within and the SNAP-25 pan (total) ratio between the anatomical areas BA9 and BA24.
All subjects were first separated into groups based on smoking status (yes, n = 21; no, n = 8), family psychiatric history (yes, n = 7; no, n = 19), handedness (right, n = 22; left, n = 5), gender (male, n = 21; female, n = 8) and ethnic heritage (Hispanic, n = 7; Anglo-American, n = 22). Those that smoked had a significantly lower pH (p = 0.04) and elevated SNAP-25a BA9 (p = 0.004) compared to nonsmokers ( table 2 ; fig. 2 a) . No significant correlations were found between SNAP-25a BA9 protein and pH in smokers (p = 0.1) or nonsmokers (p = 0.3). There was no statistical difference between the numbers of male and female smokers (p = 0.85; male smokers, n = 15; male nonsmokers, n = 6; female smokers, n = 6; female nonsmokers, n = 2). As we were interested in gender differences, we subdivided the smoking and nonsmoking subjects according to gender. Figure 2 b shows that the SNAP25a BA9 protein differences were found only in men (p = 0.01). No other significant differences in protein were found between these groups. The symptom severity at the end of life was likewise similar across groups (data not shown), except that those with a family psychiatric history were younger and had more severe symptoms ( table 3 ).
We then examined SNAP-25 protein within the affected groups (those with BP and schizophrenia), looking at prescribed psychotropic medication use (n = 6 without medication and n = 11 with medication), drug use (n = 15 without drugs and n = 2 with drugs) and suicide (n = 11 without suicide and n = 6 with suicide), which did not show any differences. From the combined BP and schizophrenia groups, we recategorized the samples into those affected with a diagnosis of AUD and those affected but without AUD diagnosis, and compared these two groups with normal controls ( table 4 ). Using family history of psychiatric illness and handedness as covariates, we found that SNAP-25b isoform protein levels in BA24 were significantly lower in subjects with AUD compared to those with no AUD and normal controls [F(4, 18) = 3.1; p = 1 Significant difference (p < 0.05) between the normal control and AUD and between normal control and no AUD. 2 Significant difference (p < 0.05) between normal control and no AUD. 3 Significant difference (p < 0.05) between normal control and AUD. figure 3 a. There was no difference in symptom severity between affected groups (AUD and no AUD), and both the AUD and no AUD groups were significantly more symptomatic than normal controls ( table 4 ; figure 3 b).
SNAP-25 Isoform Expression in Human Brain
There were significant differences in symptom severity at the end of life when comparing controls with subjects with BP or schizophrenia ( fig. 4 a; table 5 ). Using RNA integrity number and family history of psychiatric illness as covariates, no significant SNAP-25 protein differences were identified ( table 6 ; fig. 4 b, c) .
We then hypothesized that symptom type and severity, rather than clinical diagnosis, would have an effect on SNAP-25 levels. Using the BISS mood state assessment data from the last week and Barratt Impulsiveness Scale, we looked at lifetime impulsiveness, total BISS severity score, BISS depression, BISS mania subgroups and BISS irritableness. The BISS anxiety and BISS psychosis groups were merged to a single combined anxiety-psychosis group because the subjects substantially overlapped (85%). All symptom groups were in turn subdivided into high and low severity groups. Using family psychiatric history as a covariate, no significant protein differences were noted.
SNAP-25 mRNA Level
We then looked at mRNA levels. Using the category divisions described above, we found smokers had a higher pan (total) SNAP-25 BA9/BA24 mRNA ratio (p = 0.04; fig. 2 c) . We divided the smokers into affected (BP and schizophrenia) and nonaffected (normal control). Figure  2 d shows that the SNAP-25 pan (total) mRNA BA9/BA24 smoking finding was only in the affected sample (p = 0.03). No significant correlations were found with pan (total) SNAP-25 BA9/BA24 ratio pH (smoking, p = 0.9; nonsmoking, p = 0.3). SNAP-25a and SNAP-25b isoforms in BA9 mRNA were significantly higher in the Anglo-American subjects compared to Hispanics (p = 0.03 and 0.01, respectively), and there was a trend for elevation in SNAP-25a BA24 (p = 0.06; fig. 5 a-c) .
There were no significant mRNA differences within affected groups (those with BP and schizophrenia), looking at prescribed psychotropic medication use, drug use and suicide. There was also no difference in SNAP-25 mRNA between the BP, schizophrenia and normal control groups ( table 6 ; fig. 4 b) . Figure 6 a shows the pan (total) SNAP-25 BA9/BA24 ratio [F(5, 12) = 3.7; p = 0.03] was significantly elevated in both the high and low combined anxiety-psychosis groups compared to normal control (pairwise comparisons: low-normal control groups, p = 0.07; high-normal control, p = 0.01). There was no significant difference in Psychiatric symptom level at the end of life: Barratt (Barratt Impulsiveness Scale), BPRS (Brief Psychiatric Rating Scale), total BISS (total BISS score), depression (BISS depression factor score), mania (BISS factor score), irritability (BISS irritability factor score), anxiety (BISS anxiety factor score) and psychosis (BISS psychosis factor score). 1 = Significant difference (p < 0.05) between the normal control and AUD and between normal control and no AUD; 2 = significant difference (p < 0.05) between normal control and no AUD; 3 = significant difference (p < 0.05) between normal control and AUD. There were no significant differences in symptoms between the AUD and no AUD groups. Error bars = ±1 SD. 228 the number of smokers between groups (no smoking low symptom, n = 0; no smoking high symptom, n = 2; no smoking normal control, n = 4; smoking low symptom, n = 6; smoking high symptom, n = 8; smoking normal control, n = 12), as demonstrated above. The nonsmoker pan (total) SNAP-25 BA9/BA24 ratio was greater than that of the smokers and represented a potential confounding factor. We reanalyzed the average combined anxiety-psychosis data without the nonsmokers [F(3, 10) = 4.9; p = 0.024] ( fig. 6 b) . SNAP-25a BA24 was also significantly higher in the low symptom group compared to control [F(3, 19) = 4.7, p = 0.013; pairwise comparison between Psychiatric symptoms, SNAP-25 mRNA and protein level in BP, schizophrenia and normal controls. a Psychiatric symptom level at the end of life: Barratt (Barratt Impulsiveness Scale), BPRS (Brief Psychiatric Rating Scale), total BISS (total BISS score), depression (BISS depression factor score), mania (BISS factor score), irritability (BISS irritability factor score), anxiety (BISS anxiety factor score) and psychosis (BISS psychosis factor score). 1 = Significant (p < 0.05) difference between normal control and BP, and between normal control and schizophrenia groups; 2 = significant difference (p < 0.05) between normal control and schizophrenia, and nonsignificant (p = 0.07) difference between normal control and BP; 3 = significant difference between normal control and BP, and nonsignificant difference (p = 0.06) between normal control and schizophrenia groups. Error bars = ±1 SD. b SNAP-25 mRNA levels. c SNAP-25 protein levels. d SNAP-25b/a BA24 protein and mRNA levels; SNAP-25b/a BA24 ratio, and pan (total) SNAP-25 mRNA BA9/BA24 ratio.
the low symptom and normal control groups: p = 0.004 ( fig. 6 c) ]. Finally, we looked at the correlations between SNAP-25 mRNA and protein isoforms in BP, schizophrenia and normal controls. We found that in the normal control group, SNAP-25b BA24 protein to mRNA had an R 2 of -0.8 (p = 0.01). In the schizophrenia group, SNAP-25a BA9 had an R 2 of -0.8 (p = 0.2).
Discussion
This report examining SNAP-25 isoform gene expression and protein levels in human postmortem tissue does not show differences in SNAP-25 isoforms across DSM diagnostic categories of BP and schizophrenia. Rather, we found changes related to ethnicity, substance exposure and mood state at the end of life. We had data on three substance group exposures: medications, alcohol and tobacco. Medications did not show any changes; however, both alcohol and tobacco did. The pathophysiology of ACC (BA24) SNAP-25b in AUD and smoking are unknown. However, there is evidence that alcohol's neurotoxicity can cause anterior cingulate atrophy [31] with a lower level of a noradrenalin marker [32] . SNAP-25 is involved with multiple neurotransmitters [11] , including noradrenalin [33] [34] [35] . The lower level of ACC SNAP-25b implies that the noradrenergic deficits could be mediated through SNAP-25. Nicotinic acetylcholinergic receptors are widely distributed throughout the brain [36, 37] . 3 Data not available for 3 subjects. 4 Significant (p < 0.05) difference between normal control and BP, and between normal control and schizophrenia groups. 5 Significant difference (p < 0.05) between normal control and schizophrenia groups. Table 6 . SNAP-25 levels in BP and schizophrenia groups and normal controls Values are expressed as mean ± SD. Smoking activates both the prefrontal cortex (BA9) and ACC (BA24) [38, 39] . It is possible that the reduced pan (total) SNAP-25 BA9/BA24 ratio reflects smoking-induced alteration of the brain's acetylcholinergic distribution. These hypotheses can be directly evaluated with animal modeling. The data show that the amount of SNAP-25b BA9 mRNA is lower in individuals of Hispanic origin compared to those of Anglo-American origin. There has been little to no work examining the molecular biological difference in psychiatric disorders between ethnicities. However, there is a growing literature studying differences in protective and genetic risk factors in substance use disorders across ethnicities. With some of these genetic differences located in neurotransmitter receptors, there may be associated differences in protein functioning [40, 41] . This finding implies that postmortem molecular biology studies need to take into account the ethnicities of the subjects.
Our data showed that the individuals in the lower combined anxiety-psychosis symptom group had higher SNAP-25a B24 mRNA levels, which changed the isoform balance. This may be one mechanism where subtle changes in exocytotic proteins can cause or reflect human behavior. We feel the data support the idea that in postmortem research of SNAP-25, looking at the symptoms themselves rather than DSM diagnoses of BP and schizophrenia is important to understand the underlying biology.
Previous work has looked at pan (total) SNAP-25 in both BP and schizophrenia. For BP, there are only a few studies. They show either regional or no differences in pan (total) SNAP-25 [14, 17, 42] , and our data support that pan (total) SNAP-25 is not differentially expressed in BP. Conversely, SNAP-25 and other exocytotic proteins have been extensively studied in schizophrenia [12, [42] [43] [44] [45] [46] [47] [48] . These results are inconsistent and show a large variety of differential anatomical expression. One hypothesis explaining these results is that the findings are associated with the clinical syndrome of schizophrenia. An alternative hypothesis is that exocytotic proteins in- cluding SNAP-25 are sensitive to change based on a variety of nonspecific conditions including perinatal hypoxia and diabetes [49, 50] . Our findings support the latter idea that variances in SNAP-25 levels across psychiatric groups may have more to do with the characteristics of the specific populations and not the clinical psychiatric diagnoses.
Another interesting possibility of SNAP-25's role in schizophrenia is seen in a study of SNARE complexes. The authors show that the individual SNARE components, including SNAP-25 levels, were not different between the schizophrenia and control subjects. Rather, they found greater SNARE complex formation in schizophrenia. The authors suggest it is not the total quantity of the SNARE components; instead, it is the binding affinities of the individual components that are different in schizophrenia [51] .
To reduce confounding factors across diagnostic groups, we utilized tissue from only a single hemisphere [52] [53] [54] , tissue of good RNA quality [52] , and BP, schizophrenia and normal control groups matched for gender, handedness and smoking history [55] . We also looked at drugs of abuse and medication effects on SNAP-25 within the affected subjects. However, due to the great number of variables, it was not possible to have homogenous groups. To address this and multiple testing errors, we used statistical adjustments, or in the case of smoking we removed the nonsmoking subjects from the analysis and reanalyzed the data. We also subdivided the groups when the sample was large enough to provide meaningful data, i.e. symptom groups subdivided by smoking status. In the case of SNAP-25a BA24 mRNA, its amount was found to be higher in Anglo-American subjects and the low combined anxiety-psychosis symptom group, but we were unable to subdivide the sample due to the small number of Hispanic subjects. Future analysis with a greater sample size will be needed to have the power to answer whether the individual BISS factor groups of irritability, anxiety and psychosis have separate SNAP-25 differences or only as a group. The issue of medication exposure is difficult to address in postmortem research. While we demonstrate that there are no differences in SNAP-25 between the affected subjects taking medications and those not taking medications at the time of death, we cannot rule out that a lifetime expose could have had some effect. This issue can more fully be addressed with animal models.
There were only two significant correlations between mRNA and protein levels. The reasons for the lack of correlations are complex, ranging from experimental, i.e. sensitivity and measurement error, to biological, i.e. epigenetic control of gene expression [56] . Using animal modeling will be better at answering the reasons for limited protein and mRNA correlations.
In conclusion, this work looked at the influences on SNAP-25 total and isoform expression in the human brain. It appears that SNAP-25 can be a valuable biomarker for behavior and psychopathology, but less so to distinguish BP from schizophrenia. Our work, as with most postmortem research, should be used to help improve animal models of mental illness and normal behavior.
